Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Content from MarketBeat.com Is Abbott's January Pullback a Good Time to Buy? Authored by Thomas Hughes. Article Posted: 1/24/2026. 
Key Takeaways - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories (NYSE: ABT)'s January 2026 pullback has made the stock look attractively valued. The move—driven more by market angst than by company-specific weakness—appears to be a knee-jerk overreaction that has pushed the shares back into the buy zone. 
The former CEO of Google calls it the most important thing to happen in 500, maybe 1,000 years of human society. A former U.S. Treasury Secretary says when your great-grandchildren write the history of this period, the political headlines will be the second or third story. The first story is something none of us have seen before. The dot-com collapse, global financial crisis, and COVID-19 pandemic don't compare to what's coming next. We may be entering a period of dramatic, almost unimaginable change. See the full warning and how to prepare now. This buy zone lines up with the 2022–2024 trading range, when Abbott was recovering from a post–COVID-19 revenue contraction and institutions were actively accumulating shares. Abbott Laboratories Growth Accelerates The most that can be said about Abbott's Q4 results and guidance is that some metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings grew at an accelerated pace. Revenue growth missed by several hundred basis points, but margin strength offset much of the shortfall: adjusted earnings per share (EPS) rose 12%, slightly above consensus. By segment, the results highlighted the strength of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted—Nutrition down nearly 9%—but that weakness was offset by solid growth in Established Pharmaceuticals and Med Tech. Established Pharmaceuticals grew about 9%, driven by generics and emerging markets, while Med Tech rose 12.3% with broad-based strength. Margins improved as well, though they landed a bit below some analyst forecasts. A shift in product mix toward higher-margin Med Tech, reduced COVID-19-related sales and operational improvements helped drive margin expansion. Management expects earnings to improve roughly 10% in 2026, outpacing revenue growth and supporting the company's capital-return plans. Abbott's capital returns are a central part of the investment case. The company is a Dividend King, having increased its payout for more than 50 consecutive years, and its payout ratio is below 50% of consensus EPS, leaving room for share buybacks. Buybacks can help offset the dilutive impact of share-based compensation while supporting total shareholder return; the stock yields about 2.5% after the decline. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue shortfall, but there were no major rating or price-target cuts the morning of the earnings release. The prevailing view is that this fundamentally healthy company can continue returning capital while reinvesting for growth, and the longer-term outlook remains constructive. MarketBeat's consensus share price target implies up to roughly 30% upside, potentially putting the stock back near all-time highs; even the lower-end targets suggest some positive upside from current levels. Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion and strategic acquisitions. The acquisition of Exact Sciences, for example, would broaden revenue and profit streams and expand Abbott's product pipeline. That said, the recent sell-off has been steep and further downside is possible. Institutions accumulated shares through 2025 and are likely buyers at these discounted levels, which could help stabilize the stock. Early technical support appears near $105–$110, though it is not yet confirmed. Downside risk could push shares toward the low end of the buy zone—around $95 or below—before any sustained rebound.
| 
